I don't understand a lot of this BUT they can cure herpes with CRISPR/Cas9 This explains what is CRISPR/Cas9 They are genes used to help eliminate invading genetic material https://www.neb.com/tools-and-resources/feature-articles/crispr-cas9-and-targeted-genome-editing-a-new-era-in-molecular-biology Abstract RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection http://www.ncbi.nlm.nih.gov/pubmed/25157128 Latent viral infection is a persistent cause of human disease. Although standard antiviral therapies can suppress active viral replication, no existing treatment can effectively eradicate latent infection and therefore a cure is lacking for many prevalent viral diseases. The prokaryotic immune system clustered regularly interspaced short palindromic repeat (CRISPR)/Cas evolved as a natural response to phage infections, and we demonstrate here that the CRISPR/Cas9 system can be adapted for antiviral treatment in human cells by specifically targeting the genomes of latent viral infections. Patient-derived cells from a Burkitt's lymphoma with latent Epstein-Barr virus infection showed dramatic proliferation arrest and a concomitant decrease in viral load after exposure to a CRISPR/Cas9 vector targeted to the viral genome. full text http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246930/
I don't know BD but the authors are Department of Bioengineering. 2Department of Bioengineering, Department of Applied Physics, and Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305 [email protected]. we can try calling or emailing to find out
ugh names didn't copy ... Jianbin Wanga and Stephen R. Quake Department of Bioengineering. 2Department of Bioengineering, Department of Applied Physics, and Howard Hughes Medical Institute, Stanford University, Stanford, CA 94305 [email protected].
interesting there are more studies by different Drs/Reserachers that state the same thing http://www.ncbi.nlm.nih.gov/pubmed/24788700 High-efficiency targeted editing of large viral genomes by RNA-guided nucleases. Bi Y1, Sun L1, Gao D1, Ding C1, Li Z1, Li Y1, Cun W1, Li Q1. Author information 1Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China; Yunnan Key Laboratory of Vaccine Research and Development of Severe Infectious Disease, Kunming, Yunnan, China. Abstract A facile and efficient method for the precise editing of large viral genomes is required for the selection of attenuated vaccine strains and the construction of gene therapy vectors. The type II prokaryotic CRISPR-Cas (clustered regularly interspaced short palindromic repeats (CRISPR)-associated (Cas)) RNA-guided nuclease system can be introduced into host cells during viral replication. The CRISPR-Cas9 system robustly stimulates targeted double-stranded breaks in the genomes of DNA viruses, where the non-homologous end joining (NHEJ) and homology-directed repair (HDR) pathways can be exploited to introduce site-specific indels or insert heterologous genes with high frequency. Furthermore, CRISPR-Cas9 can specifically inhibit the replication of the original virus, thereby significantly increasing the abundance of the recombinant virus among progeny virus. As a result, purified recombinant virus can be obtained with only a single round of selection. In this study, we used recombinant adenovirus and type I herpes simplex virus as examples to demonstrate that the CRISPR-Cas9 system is a valuable tool for editing the genomes of large DNA viruses.